Yatin Suneja
Stock Analyst at Guggenheim
(2.13)
# 2,707
Out of 4,784 analysts
122
Total ratings
40.95%
Success rate
-7.42%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Reiterates: Buy | $15 | $1.27 | +1,085.77% | 2 | Mar 26, 2025 | |
| IFRX InflaRx | Maintains: Buy | $7 → $10 | $1.15 | +769.57% | 5 | Mar 26, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $2.35 | +1,006.38% | 4 | Mar 25, 2025 | |
| ACET Adicet Bio | Reiterates: Buy | $7 | $0.83 | +743.17% | 1 | Mar 21, 2025 | |
| IMVT Immunovant | Reiterates: Buy | n/a | $18.37 | - | 8 | Mar 20, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Buy | $84 | $19.99 | +320.21% | 1 | Mar 12, 2025 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $45 | $8.17 | +450.80% | 3 | Mar 12, 2025 | |
| ARGX argenx SE | Maintains: Buy | $775 → $1,100 | $589.15 | +86.71% | 9 | Mar 10, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | n/a | $1.03 | - | 2 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $165 → $163 | $113.16 | +44.04% | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $1.91 | - | 3 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $11.01 | +308.72% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $17.07 | +17.16% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $36 | $18.95 | +89.97% | 11 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.71 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $16.65 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $17.94 | +262.32% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $38.66 | +339.73% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,180 → $1,300 | $637.36 | +103.97% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $5.64 | +467.38% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.22 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $6.43 | +677.60% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $19.93 | +351.58% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $118.53 | +5.46% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $10.38 | +54.14% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $39.86 | +93.18% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $1.55 | +2,093.55% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.12 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $34.26 | +43.02% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $5.83 | +843.40% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $138.37 | +152.95% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.28 | - | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $30 | $6.60 | +354.55% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.30 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $14.13 | +69.85% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $62.70 | -45.77% | 2 | Jan 14, 2020 |
Zura Bio
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $1.27
Upside: +1,085.77%
InflaRx
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $1.15
Upside: +769.57%
Larimar Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: $26
Current: $2.35
Upside: +1,006.38%
Adicet Bio
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.83
Upside: +743.17%
Immunovant
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $18.37
Upside: -
Dianthus Therapeutics
Mar 12, 2025
Reiterates: Buy
Price Target: $84
Current: $19.99
Upside: +320.21%
Zenas BioPharma
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $8.17
Upside: +450.80%
argenx SE
Mar 10, 2025
Maintains: Buy
Price Target: $775 → $1,100
Current: $589.15
Upside: +86.71%
Neumora Therapeutics
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.03
Upside: -
Neurocrine Biosciences
Feb 10, 2025
Maintains: Buy
Price Target: $165 → $163
Current: $113.16
Upside: +44.04%
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $1.91
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $11.01
Upside: +308.72%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $17.07
Upside: +17.16%
Dec 12, 2024
Maintains: Buy
Price Target: $90 → $36
Current: $18.95
Upside: +89.97%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.71
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $16.65
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $17.94
Upside: +262.32%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $38.66
Upside: +339.73%
Aug 2, 2024
Maintains: Buy
Price Target: $1,180 → $1,300
Current: $637.36
Upside: +103.97%
Jul 23, 2024
Initiates: Buy
Price Target: $32
Current: $5.64
Upside: +467.38%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Apr 29, 2024
Initiates: Buy
Price Target: $50
Current: $6.43
Upside: +677.60%
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $19.93
Upside: +351.58%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $118.53
Upside: +5.46%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $10.38
Upside: +54.14%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $39.86
Upside: +93.18%
Aug 14, 2023
Reiterates: Buy
Price Target: $34
Current: $1.55
Upside: +2,093.55%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.12
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $34.26
Upside: +43.02%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $5.83
Upside: +843.40%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $138.37
Upside: +152.95%
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $8.28
Upside: -
Nov 11, 2022
Maintains: Buy
Price Target: $42 → $30
Current: $6.60
Upside: +354.55%
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.30
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $14.13
Upside: +69.85%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $62.70
Upside: -45.77%